Orchid Pharma Quarterly Results for Trading Insights
In Sept 2025, Orchid Pharma (ORCHPHARMA) reported revenue ₹204 Cr and net profit ₹-6 Cr — revenue -11.3% YoY. For annual financials, live price and key ratios, visit ORCHPHARMA company profile.
ORCHPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Orchid Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with Orchid Pharma valuation methods to assess whether the stock is under or overvalued.
- Revenue of ₹204 Cr in Sept 2025 (-15.4% vs Mar 2025, -11.3% vs Sept 2024)
- Net Profit of ₹-6 Cr in Sept 2025 (-127.3% vs Mar 2025, -122.2% vs Sept 2024)
- EBITDA of ₹9 Cr in Sept 2025 (-71.9% vs Mar 2025)
- Operating Margin of -1.0% in Sept 2025 (-13.0pp vs Mar 2025)
- Earnings Per Share of ₹-1.13 in Sept 2025 (-125.7% vs Mar 2025)
Orchid Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ORCHPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 204 | 241 | 184 | 213 | 230 | -15.4% | -11.3% |
| Net Profit (₹ Cr) | -6 | 22 | 15 | -13 | 27 | - | - |
| EBITDA (₹ Cr) | 9 | 32 | 26 | 0 | 38 | - | - |
| EPS (₹) | -1.13 | 4.40 | 2.94 | -2.49 | 5.37 | - | - |
| Operating Margin (%) | -1.0% | 12.0% | 8.0% | -3.0% | 14.0% | - | - |
ORCHPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Orchid Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse Orchid Pharma ownership structure to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ORCHPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Orchid Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1652.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 127.1 |
|
Divis Laboratories
Sept 2025 |
₹162,373.86 Cr | 6070.0 | 2,860 | 689 | +7.1% | - | 24.1% | 233.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4181.0 | 3,219 | 591 | +11.3% | - | 18.4% | 238.4 |
|
Lupin
Sept 2025 |
₹106,664.75 Cr | 2315.1 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.5 |
|
Dr Reddys Laborator…
Sept 2025 |
₹102,844.71 Cr | 1235.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
All amounts in ₹ Crores